Childhood cancer survivors usually are advised to follow up their heart health and do a screening to detect heart dysfunction caused by anthracycline induce cardiotoxicity. A new study published online June 21, 2018, in Clinical Cancer Research, a journal of the American Association for Cancer Research, presents a new breakthrough electronic wireless device called Vivio, developed by Caltech with City of Hope that can detect heart dysfunction in childhood cancer survivors treated with anthracycline chemotherapy. This accessible technology has the potential to revolutionize the practice of clinicians caring for a large number of patients diagnosed with cardiac dysfunction and heart failure.
“The pediatric oncology community is becoming increasingly aware that there are new issues faced by many cancer survivors that may not manifest themselves until decades after their cancer treatment is done,” said Saro Armenia, DO, MPH, director of the Childhood Cancer Survivorship Clinic, City of Hope, Duarte, California. “One of these issues is a higher burden of cardiovascular disease, which can result from exposure to anthracyclines [a class of chemotherapy] as part of their cancer treatment.”
It is important to point out that Vivio is not intended to replace the echocardiogram or cardiac MRI, Rather, it’s a way to bring screening technology out of the cancer center and into the community.